Further, our findings suggested that NK-2R antagonist SR48968 inhibited the proliferation of myeloid leukemia cells by augmenting mitochondrial calcium overload and expediting ROS production, consequently inducing necroptosis (Fig. 1K), thereby shedding light on the potential value of targeting NK-2R as a therapeutic strategy to combat leukemia. This evidence concerns the gene TACR2 and myeloid leukemia.